Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by TriumphSpitSixon Jul 10, 2020 11:30pm
262 Views
Post# 31254665

RE:Thoughts on Bio Pub

RE:Thoughts on Bio PubThe guy's "wait until the RS to invest" question is flawed to begin with because it presumes the stock price will fall post-consolidation. That won't necesarily happen with Antibe on the upswing. Only companies that do it so they can then finance to keep the lights on should see a drop post-RS. But alas, the psychology accompanying a share consolidation in the mind of the average investor is somthing like, they "lost" some of their shares, so that means they also "lost" value/money when that's clearly not the case. It's a stupid phenomenon but many "investors" are panicky animals.

Also, Dan didn't "struggle" to answer the question. He was trying to gently explain that 1.) the company has been significantly de-risked by the excellent Ph. 2B dose-ranging results, 2.) that retail mis-understood the results (the Ph. 2/3 adaptive language) and 3.) yes, that because of this, they are undervalued.
<< Previous
Bullboard Posts
Next >>